HomeAbout BiovailInvestor RelationsProductsCareersSite MapContact Us
Financials

Stock Watch
Earnings Estimate
Fundamentals
Shareholder Reports
Webcasts
Regulatory Filings
Product Pipeline

About Biovail

Corporate Governance
Executive Team
Affiliated Companies
Press Room
Investor Contacts

Analysts
Request Investor Information
Corporate Fact Sheet

2005 Annual Report

PDF Version
Interactive Version


24.01 24
up0.16 | 0.67% 259,945
24.02 | 23.75 23.99
Sep 02 2010 11:11 AM 24.01
24.25
12.14
3,808,034,020 0.9
158,602,000 26.6778
Stock Chart
Note: The stock price performance shown on the quote above is not necessarily indicative of the future price performance

Copyright © 1998-2002 MarketWatch.com Inc. User agreement applies. Historical and current end-of-day data provided by Interactive Data Corp. Intraday data is at least 20-minutes delayed. All times are EDT. Intraday data provided by S&P Comstock and subject to terms of use.
Tools

Email Alerts
Tools
Q2 2010 Financial Results

Valeant - Biovail Analyst Investor Presentation

Biovail - Valeant Merger Conference Call

Biovail's Product Pipeline

Pimavanserin Schizophrenia Co-Therapy - Phase 2 Data

Aplenzin Prescribing Information

Nitoman Prescribing Information

Xenazine Prescribing Information

Xenazine Medication Guide

Corporate Fact Sheet

IMPORTANT: Income Tax Information for Canadian Resident Shareholders


Download Adobe Acrobat Reader
Tools